Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14230249 | 0.85 | PNMT (0.60) | HTR2AHTR2BHTR2CPNMTTAAR1 | |
| SCHEMBL8539519 | 0.84 | GABRA1 (0.50) | HTR2AHTR2BHTR2CGABRA1GABRB2 | |
| SCHEMBL26054333 | 0.79 | OPRM1 (0.44) | HTR2AHTR2BHTR2CTAAR1SLC6A2 | |
| SCHEMBL2623871 | 0.78 | TAAR1 (0.50) | HTR2AHTR2BHTR2CTAAR1SLC6A2 | |
| SCHEMBL28161128 | 0.77 | CTSS (0.48) | HTR2AHTR2BHTR2CGABRA1GABRB2 | |
| SCHEMBL9248105 | 0.76 | HTR2A (0.44) | HTR2AHTR2BHTR2CGABRA1GABRB2 | |
| SCHEMBL598282 | 0.76 | TAAR1 (0.52) | GABRA1GABRB2PNMTTAAR1SLC6A2 | |
| SCHEMBL23665723 | 0.75 | CA2 (0.44) | LMNAMAPTOPRK1 | |
| SCHEMBL8046780 | 0.75 | — | — | |
| SCHEMBL22508191 | 0.74 | GABRA1 (0.42) | HTR2AHTR2BHTR2CGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| US-20210221843-A1 | EPHA2 AGONISTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-07-22 | — | — | US | disclosed |
| US-20150045436-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2015-02-12 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221843-A1 | EPHA2 AGONISTS AND USES THEREOF | EPHA2, EPHB2, EPHA6 | HTR2A 975/4885HTR2B 1208/4885HTR2C 1523/4885 |
| US-20150045436-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | HTR2A 1675/4885HTR2B 1522/4885HTR2C 781/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | HTR2A 3518/4885HTR2B 3910/4885HTR2C 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.